Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Rhea-AI Summary

Apogee Therapeutics (Nasdaq: APGE) entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive capital to advance Phase 3 development and potential commercialization of zumilokibart.

The deal includes up to $800 million in synthetic royalty funding and access to up to $500 million in senior corporate debt. Combined with Apogee’s $1.3 billion in cash, the company believes this supports a self-sustainable financial profile through commercialization without future equity financing.

Positive

• Up to $1.3 billion in flexible, non-dilutive total capital
• Synthetic royalty funding up to $800 million tied to zumilokibart sales
• Initial $400 million preapproval funding in milestone-based tranches
• Up to $400 million additional funding available upon FDA approval
• Access to up to $500 million in senior corporate debt if mutually agreed
• Company reports combined $1.3 billion cash plus facility supports commercialization without new equity

Negative

• Low-to-mid single digit tiered royalties on zumilokibart sales for 15 years
• No royalties only on global annual zumilokibart sales exceeding $8 billion
• Cash runway end date guidance removed, reducing explicit visibility on runway duration
• Use of up to $500 million senior debt would add financial leverage

News Market Reaction – APGE

-6.11%

8 alerts

-6.11% Session close to close

-18.4% Trough in 1 min

$6.24B Market Cap

1.16K Volume

In the May 27 session, APGE declined 6.11%, reflecting a notable negative market reaction. Argus tracked a trough of -18.4% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.1% in the session following this news. A negative reaction despite the sizable no...

Analysis

The stock moved -6.1% in the session following this news. A negative reaction despite the sizable non-dilutive package of up to $1.3 billion would fit a pattern where markets occasionally fade financing headlines or focus on execution risk. Historically, Apogee’s stock has sometimes sold off on capital‑raising news even when pipeline updates were constructive. Elevated short positioning and prior insider selling could have reinforced downside pressure, making it important to watch future clinical milestones and balance‑sheet updates for shifts in sentiment.

Key Figures

Total strategic capital: $1.3 billion Synthetic royalty funding: $800 million Senior corporate debt: $500 million +5 more

8 metrics

Total strategic capital $1.3 billion Maximum non-dilutive funding from Blackstone collaboration

Synthetic royalty funding $800 million Up to amount tied to zumilokibart royalties

Senior corporate debt $500 million Maximum senior debt available at mutual consent

Current total cash $1.3 billion Company’s stated cash balance prior to transaction

Preapproval funding $400 million Initial preapproval synthetic royalty funding across 3 tranches

Post‑approval funding $400 million Additional funding available upon FDA approval of zumilokibart

Royalty term 15 years Duration of synthetic royalty on worldwide zumilokibart sales

Royalty sales cap $8 billion No royalties due on annual sales above this level

Historical Context

5 past events · Latest: May 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	Earnings and pipeline	Positive	+1.9%	Q1 2026 results with cash up to $1.3B and pipeline progress.
Mar 26	Equity offering close	Negative	-0.8%	Closing of $403M underwritten equity offering at $70 per share.
Mar 24	Offering pricing	Negative	+7.6%	Pricing of $350M underwritten offering at $70 per share.
Mar 23	Proposed offering	Negative	-7.9%	Announcement of proposed $300M common stock offering.
Mar 23	Clinical data update	Positive	+20.0%	Positive 52‑week Phase 2 Part A results for zumilokibart in dermatitis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions skew toward alignment: positive clinical and financing updates have mostly produced moves in the expected direction, with one notable divergence on an offering pricing.

Recent Company History

Over the last few months, Apogee has combined financing activity with steady progress for zumilokibart. A March 2026 clinical update reported strong Phase 2 Part A 52‑week results and drove a nearly 20% gain, while multiple equity offerings around late March showed mixed but generally aligned reactions. Early May 2026 earnings highlighted a cash balance of $1.3 billion and extended runway, which the market received modestly positively. Today’s large non‑dilutive funding continues this pattern of strengthening the balance sheet to support late‑stage development.

Key Terms

synthetic royalty, senior corporate debt, royalty financing, Phase 3, +4 more

8 terms

synthetic royalty financial

"including up to $800 million of synthetic royalty and access of up to $500 million"

A synthetic royalty is a financial arrangement where one party receives payments that mimic the income from a traditional royalty, like earnings from a patent or natural resource, without owning the underlying asset. It allows companies or investors to replicate the financial benefits of royalties through contractual agreements, often for strategic or tax reasons. For investors, understanding synthetic royalties helps assess how a company generates income and the potential risks involved.

senior corporate debt financial

"including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt"

Senior corporate debt is money a company borrows through loans or bonds that must be repaid before other obligations if the company runs into trouble. Because holders have first claim on assets and cash flows, these instruments are generally safer than subordinated or unsecured debt and tend to offer lower interest rates. Investors watch senior debt to gauge recovery prospects in defaults and to balance risk versus yield in a portfolio.

royalty financing financial

"This is the largest royalty financing for a pre-Phase 3 program to date."

Royalty financing is a way for a business to raise money by selling a share of future revenue or product sales in exchange for upfront cash; the investor is paid back as the company earns money, like buying a claim on a slice of each future sale. It matters to investors because returns depend on the company’s actual sales rather than its profits or stock price, offering potential steady income if products perform well but carrying risk if revenue falls short.

Phase 3 medical

"to support the continued development and potential commercialization of zumilokibart through Phase 3 development"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

Phase 2 medical

"Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

atopic dermatitis medical

"therapy for moderate-to-severe atopic dermatitis, said Michael Henderson, M.D."

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

FDA approval regulatory

"Upon FDA approval of zumilokibart, up to $400 million in additional funding is available"

FDA approval is the U.S. Food and Drug Administration’s formal authorization for a drug, vaccine, or medical device to be marketed and sold after reviewers determine it meets standards for safety and effectiveness. For investors it’s a pivotal milestone because it opens the door to legal, large-scale sales and can sharply boost revenue potential while reducing regulatory uncertainty—like receiving a safety certificate that lets a new bridge carry traffic and tolls.

Form 8-K regulatory

"found in the Current Report on Form 8-K filed by the company today"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt 

Combined with company's current total cash of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart without need for future equity financing

Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m. Eastern Time

SAN FRANCISCO and BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences (“Blackstone”) for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart.

“Our partnership with Blackstone Life Sciences represents a major milestone in the advancement of zumilokibart as the next meaningful first line therapy for moderate-to-severe atopic dermatitis,” said Michael Henderson, M.D., Chief Executive Officer of Apogee Therapeutics. “This collaboration provides non-dilutive flexible funding at an attractive cost of capital for the late-stage development of zumilokibart and establishes a path to commercialization and profitability for Apogee. As supported by our Apex Part B data announced today, we believe zumilokibart has the potential to be a transformative therapy for patients with differentiated efficacy and dosing in atopic dermatitis and other large I&I indications.”

“We are excited to support Apogee's advancement of zumilokibart through Phase 3 development and potential commercialization,” said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. “Our collaboration with Apogee is a great example of our strategy to provide leading biotechnology companies with non-dilutive financing at scale and the resources and flexibility to further scientific innovation and invest in the advancement of their pipelines."

Added Kiran Reddy, M.D., Senior Managing Director, Blackstone Life Sciences, "This is the largest royalty financing for a pre-Phase 3 program to date. It reflects our conviction that zumilokibart has the potential to become a highly differentiated, multi-indication product that will have a major impact on patients' quality of life."

Transaction Overview

The collaboration agreement provides for up to $1.3 billion in flexible, non-dilutive total capital, including up to $800 million of synthetic royalty and up to $500 million of senior debt available at the mutual consent of Apogee and Blackstone.

Synthetic royalty: Blackstone will provide up to $800 million of synthetic royalty funding in exchange for low-to-mid single digit tiered royalties for a term of 15 years on worldwide annual sales of zumilokibart. The royalties decrease based on sales with no royalties on global annual sales in excess of $8 billion.

• The first $400 million in preapproval funding is divided into 3 tranches, including $100 million at signing, $100 million upon completion of zumilokibart Phase 3 enrollment, and $200 million upon positive Phase 3 data. Upon FDA approval of zumilokibart, up to $400 million in additional funding is available, $150 million of which is at Apogee’s option
• The funding agreement includes specific provisions on a change of control, with the option to buy back a significant portion of the royalty.
• Senior debt: Up to $500 million of senior corporate debt is available at mutual consent of Apogee and Blackstone
  

Additional details regarding the funding agreement can be found in the Current Report on Form 8-K filed by the company today with the U.S. Securities and Exchange Commission.

Cash runway update

As a result of entering into this funding agreement with Blackstone, the company is removing its cash runway end date guidance.

Webcast Details

Apogee Therapeutics will hold a live webcast to discuss the Blackstone transaction and the results of the APEX Phase 2 Part B trial today at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

Advisors

Goldman Sachs served as exclusive financial advisor and Latham & Watkins LLP as legal counsel to Apogee Therapeutics. Ropes & Gray LLP served as legal counsel to Blackstone Life Sciences.

About Apogee

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, eosinophilic esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

About Blackstone Life Sciences

Blackstone Life Sciences (BXLS) is a leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $17 billion in assets under management.

Forward Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Apogee’s expectations regarding: Apogee’s plans for its current and future product candidates, programs, and clinical trials, including the Phase 3 development and potential commercialization of zumilokibart and expansion of zumilokibart into additional indications; the potential clinical benefit, dosing regimen, safety and efficacy profiles and treatment outcomes of zumilokibart, including its potential to be a best-in-class therapy, be the next meaningful first line therapy for AD, overcome limitations of existing therapies, and be the new standard of care in AD; the potential for Apogee product candidates and programs to overcome limitations of existing therapies; the potential of zumilokibart to become a differentiated, multi-indication product; its planned business strategies; the financial resources available to Apogee, including the availability of capital from the synthetic royalty and potential debt arrangement and whether Apogee achieves the milestones associated with certain payments thereunder and whether Apogee elects to receive optional funding under the arrangement, if available; its expectations regarding the time period over which Apogee’s capital resources will be sufficient to fund its anticipated operations, including its self-sustainable financial profile through commercialization of zumilokibart without the need for future equity financing; its potential profitability; and estimates of market size. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Apogee believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to Apogee on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Apogee’s filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond Apogee’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Apogee’s preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of Apogee’s clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the applicability of clinical study results to actual outcomes; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Apogee’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, and subsequent disclosure documents Apogee may file with the SEC. Apogee claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Apogee expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Apogee Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Noel.Kurdi@apogeetherapeutics.com

Apogee Media Contact:
Dan Budwick
1AB Media
dan@1abmedia.com

Blackstone Life Sciences Media Contact:
David Vitek
(212) 583-5291
David.Vitek@Blackstone.com

FAQ

What is included in Apogee Therapeutics (APGE) $1.3 billion Blackstone financing announced May 27, 2026?

The collaboration provides up to $1.3 billion in non-dilutive capital. According to Apogee, this includes up to $800 million of synthetic royalty funding and access to up to $500 million in senior corporate debt, subject to mutual consent.

How does the synthetic royalty structure work in the Apogee (APGE) and Blackstone zumilokibart deal?

Blackstone will receive low-to-mid single digit tiered royalties on worldwide zumilokibart sales for 15 years. According to Apogee, royalties decline with higher sales and are not owed on global annual sales exceeding $8 billion.

What milestone-based funding tranches does Apogee (APGE) receive for zumilokibart before approval?

Apogee can receive $400 million in preapproval funding in three tranches. According to Apogee, these are $100 million at signing, $100 million upon completion of Phase 3 enrollment, and $200 million upon positive Phase 3 data.

How much additional funding can Apogee (APGE) access after FDA approval of zumilokibart?

Following potential FDA approval, Apogee may access up to $400 million more in funding. According to Apogee, $150 million of this post-approval funding is at the company’s option within the overall synthetic royalty agreement.

What does the Blackstone financing mean for Apogee (APGE) equity and cash runway?

Apogee describes the Blackstone deal as non-dilutive and supportive of a self-sustainable financial profile. According to Apogee, combined with its $1.3 billion cash, the company expects to commercialize zumilokibart without future equity financing and is removing cash runway end date guidance.

How large is the Apogee (APGE) zumilokibart royalty financing in industry context?

Blackstone calls this the largest royalty financing for a pre-Phase 3 program to date. According to Blackstone Life Sciences, the size reflects its conviction in zumilokibart’s potential as a differentiated, multi-indication product.